- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04256876
TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) (TaPaS)
A Randomized-controlled Trial Comparing Transcutaneous Tibial Nerve Stimulation (TTNS) Versus Sham Therapy on Short Term Continence Outcomes in Children With the Idiopathic Overactive Bladder Syndrome: the TaPaS Trial Part I
Part I of the TaPaS trial forms part of a twofold clinical RCT:
Part 1) A prospective RCT comparing the efficacy of transcutaneous tibial nerve stimulation (TTNS) with TTNS sham therapy for children with idiopathic overactive bladder on clinical and patient reported outcomes (PROMS).
Part 2) A prospective RCT comparing TTNS versus Percutaneous tibial nerve stimulation (PTNS) on clinical outcomes and PROMS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Non invasive neuromodulation therapy for children with the overactive bladder syndrome is a highly under investigated topic in medical literature.
Only 2 studies ( Patidar et al. and Boudaouid et al.) investigated the use of tibial nerve stimulation with adhesive electrodes.
1) In the first trial the superiority of TTNS vs.Sham therapy for the therapeutic management of children with OAB naive to any pharmacological treatment will be examined.
Clinical outcomes will be assessed by the use of daytime and nighttime bladder diaries.
Assessment of outcomes at baseline, after 6 weeks and 12 weeks of treatment, and investigation of mean time to partial or complete relapse following 6 weeks observation.
After a wash-out period of 6 weeks, patients from the part I Sham group will be able to be included for TaPaS part II.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lynn Ghijselings, MD
- Phone Number: +3293321353
- Email: lynn.ghijselings@uzgent.be
Study Contact Backup
- Name: Anne-Françoise Spinoit, Professor
- Phone Number: +3293326495
- Email: annefrançoise.spinoit@uzgent.be
Study Locations
-
-
East-Flanders
-
Gent, East-Flanders, Belgium, 9000
- University Hospital Ghent
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children between 5 and 12 years old, clinically diagnosed with the idiopathic overactive bladder syndrome with urinary incontinence (daytime and/or nighttime)
- Untreated, except from urotherapy.
Exclusion Criteria:
- Enuresis nocturna due to nocturnal polyuria
- Dysfunctional voiding
- Neurogenic bladder
- Psychiatric disorders, behavioural disturbances or mental disabilities
- Treated before with pharmacotherapy or invasive therapies for OAB
- Children with parents unable to record reliably micturition diaries.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active TTNS
Children treated by transcutaneous tibial nerve stimulation.
TENS device connected to adhesive electrodes.
Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
|
See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
Other Names:
|
Sham Comparator: TTNS sham intervention
Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld. Home therapy: Daily stimulation during 60 minutes. |
See section 'arms'
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean voided volume per void
Time Frame: 12 weeks
|
Difference in mean voided volume per void in percentage
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum voided volume (ml)
Time Frame: 12 weeks
|
Maximal voided volume per void ( ml) .
|
12 weeks
|
Number of urgency incontinence episodes / 24 h.
Time Frame: 12 weeks
|
Reduction in number of incontinence episodes per 24 hour
|
12 weeks
|
Daytime voiding frequency
Time Frame: 12 weeks
|
Mean voiding frequency per day
|
12 weeks
|
Satisfaction on urinary symptoms reported by parents
Time Frame: 12 weeks
|
Subjective satisfaction reported by the parents - on a 7 point likert scale- "How satisfied of dissatisfied would you be if the bladder symptoms of your child would persist like this?
|
12 weeks
|
Time to recurrence
Time Frame: At 12 weeks of treatment + at 6 weeks of observational period without treatment.
|
Time to complete or partial relapse to baseline symptoms after 12 weeks of treatment during the observational period of 6 weeks.
|
At 12 weeks of treatment + at 6 weeks of observational period without treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anne-Françoise Spinoit, Professor, University Hospital, Ghent
Publications and helpful links
General Publications
- Boudaoud N, Binet A, Line A, Chaouadi D, Jolly C, Fiquet CF, Ripert T, Merol ML. Management of refractory overactive bladder in children by transcutaneous posterior tibial nerve stimulation: A controlled study. J Pediatr Urol. 2015 Jun;11(3):138.e1-10. doi: 10.1016/j.jpurol.2014.09.013. Epub 2015 Mar 31.
- Patidar N, Mittal V, Kumar M, Sureka SK, Arora S, Ansari MS. Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder: A preliminary report. J Pediatr Urol. 2015 Dec;11(6):351.e1-6. doi: 10.1016/j.jpurol.2015.04.040. Epub 2015 Jul 29.
- Ghijselings L, Renson C, Van de Walle J, Everaert K, Spinoit AF. Clinical efficacy of transcutaneous tibial nerve stimulation (TTNS) versus sham therapy (part I) and TTNS versus percutaneous tibial nerve stimulation (PTNS) (part II) on the short term in children with the idiopathic overactive bladder syndrome: protocol for part I of the twofold double-blinded randomized controlled TaPaS trial. Trials. 2021 Apr 2;22(1):247. doi: 10.1186/s13063-021-05117-8.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EC/2018/1267
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder Syndrome
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Taipei Veterans General Hospital, TaiwanRecruitingOveractive Bladder SyndromeTaiwan
-
Buddhist Tzu Chi General HospitalUnknownOveractive Bladder SyndromeTaiwan
-
Radboud University Medical CenterWithdrawn
-
PfizerCompleted
-
PfizerCompletedOveractive Bladder SyndromeGermany
-
Walter Reed National Military Medical CenterRecruitingOveractive Bladder SyndromeUnited States
-
University Hospital, GhentAstellas Pharma Inc; MedtronicCompleted
-
Chung Shan Medical UniversityUnknownOveractive Bladder SyndromeTaiwan
-
Far Eastern Memorial HospitalCompletedOveractive Bladder SyndromeTaiwan
Clinical Trials on TTNS
-
University of Sao Paulo General HospitalCompletedOveractive Bladder SyndromeBrazil
-
University of ZurichSwiss National Science Foundation; Rehab Basel; Clinique Romande de Readaptation and other collaboratorsRecruitingSpinal Cord Injury, AcuteSwitzerland
-
University of ZurichRecruitingNeurogenic Bladder DysfunctionBelgium, Brazil, Italy, Switzerland
-
The University of Texas Health Science Center,...The Methodist Hospital Research Institute; MedStar National Rehabilitation...RecruitingSpinal Cord InjuriesUnited States
-
University of ZurichTerminatedNeurogenic Bladder DysfunctionSwitzerland
-
The University of Texas Health Science Center,...CompletedNeurogenic Bowel | Chronic Spinal Cord InjuryUnited States
-
Kaiser PermanenteAmerican Urogynecologic SocietyActive, not recruitingOveractive Bladder | Urge IncontinenceUnited States
-
Pamukkale UniversityNot yet recruitingUrinary Bladder, OveractiveTurkey
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedChronic Spinal Cord Injury | Neurogenic BladderUnited States
-
Pamukkale UniversityRecruitingIdiopathic Overactive Bladder | Bladder Training | Transcutaneous Tibial Nerve Stimulation | Magnetic StimulationTurkey